Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1142034 | 0.98 | AAK1 (0.47) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL4549947 | 0.95 | AAK1 (0.49) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL17772235 | 0.91 | AAK1 (0.39) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL15401660 | 0.88 | AAK1 (0.47) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL15276604 | 0.88 | AAK1 (0.47) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL2755130 | 0.88 | AAK1 (0.47) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL10215891 | 0.88 | AAK1 (0.47) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL12133462 | 0.87 | AAK1 (0.47) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL10226761 | 0.87 | AAK1 (0.49) | AAK1PRMT5WDR77USP30DGAT1 | |
| SCHEMBL16936500 | 0.87 | USP30 (0.49) | AAK1PRMT5WDR77USP30AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024187049-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024153244-A1 | NITROGEN-CONTAINING COMPOUND | 南京再明医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9375434-B2 | Antitumor effect potentiator composed of imidazooxazine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011033265-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010114780-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009148916-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | AAK1 987/4885PRMT5 703/4885WDR77 2535/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AAK1 987/4885PRMT5 703/4885WDR77 2535/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | AAK1 368/4885PRMT5 3027/4885WDR77 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.